Skip to content

Study · Non-randomized trial · n = 23 · 2013

5 results

The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients.

Imamura S, Hirai K, Hirai A

The Tohoku journal of experimental medicine1 Sept 2013Cited by 51 (Europe PMC)

PMID24064677 (opens in a new tab)DOI10.1620/tjem.231.57 (opens in a new tab)PepBankPUB-24064677
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In type 2 diabetic patients with overt diabetic nephropathy, 12 months of liraglutide lowered HbA1c from 7.4% to 6.9%.

    In plain wordsIn people with type 2 diabetes and kidney disease, 12 months of liraglutide lowered HbA1c from 7.4% to 6.9%.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 23

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c
    7.4%
    baseline
    HbA1c
    6.9%
    12 months

    Source sentences

    Summary
    Treatment with liraglutide caused a significant decrease in HbA1c from 7.4 ± 0.2% to 6.9 ± 0.3% (p = 0.04)
    1 context sentence
    Summary · context
    Twenty-three type 2 diabetic patients with overt DN, who had already been treated with blockade of renin-angiotensin system under dietary sodium restriction, were given liraglutide for a period of 12 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In type 2 diabetic patients with overt diabetic nephropathy, 12 months of liraglutide lowered BMI from 27.6 to 26.5 kg/m².

    In plain wordsIn people with type 2 diabetes and kidney disease, 12 months of liraglutide lowered BMI from 27.6 to 26.5.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index change
    Study

    n = 23

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    BMI
    27.6 kg/m²
    baseline
    BMI
    26.5 kg/m²
    12 months

    Source sentences

    Summary
    Treatment with liraglutide caused a significant decrease in HbA1c from 7.4 ± 0.2% to 6.9 ± 0.3% (p = 0.04), and in body mass index (BMI) from 27.6 ± 0.9 kg/m² to 26.5 ± 0.8 kg/m² after 12 months (p < 0.001)
    1 context sentence
    Summary · context
    Twenty-three type 2 diabetic patients with overt DN, who had already been treated with blockade of renin-angiotensin system under dietary sodium restriction, were given liraglutide for a period of 12 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In type 2 diabetic patients with overt diabetic nephropathy, systolic blood pressure did not change during 12 months of liraglutide.

    In plain wordsIn people with type 2 diabetes and kidney disease, systolic blood pressure did not change during 12 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeSystolic blood pressure
    Study

    n = 23

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Treatment with liraglutide caused a significant decrease in HbA1c from 7.4 ± 0.2% to 6.9 ± 0.3% (p = 0.04), and in body mass index (BMI) from 27.6 ± 0.9 kg/m² to 26.5 ± 0.8 kg/m² after 12 months (p < 0.001), while systolic blood pressure did not change
    1 context sentence
    Summary · context
    Twenty-three type 2 diabetic patients with overt DN, who had already been treated with blockade of renin-angiotensin system under dietary sodium restriction, were given liraglutide for a period of 12 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In type 2 diabetic patients with overt diabetic nephropathy, 12 months of liraglutide reduced proteinuria from 2.53 to 1.47 g/g creatinine.

    In plain wordsIn people with type 2 diabetes and kidney disease, 12 months of liraglutide reduced protein loss in urine.

    Peptide
    Liraglutide
    Outcome
    DecreaseProteinuria
    Study

    n = 23

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Proteinuria
    2.53 g/g creatinine
    baseline
    Proteinuria
    1.47 g/g creatinine
    12 months

    Source sentences

    Summary
    The 12-month administration of liraglutide caused a significant decrease in proteinuria from 2.53 ± 0.48 g/g creatinine to 1.47 ± 0.28 g/g creatinine (p = 0.002).
    1 context sentence
    Summary · context
    Twenty-three type 2 diabetic patients with overt DN, who had already been treated with blockade of renin-angiotensin system under dietary sodium restriction, were given liraglutide for a period of 12 months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In type 2 diabetic patients with overt diabetic nephropathy, liraglutide slowed the decline in eGFR from 6.6 to 0.3 mL/min/1.73 m²/year.

    In plain wordsIn people with type 2 diabetes and kidney disease, liraglutide slowed the yearly decline in kidney filtering.

    Peptide
    Liraglutide
    Outcome
    DecreaseRate of decline in eGFR
    Study

    n = 23

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    eGFR decline rate
    6.6 mL/min/1.73 m²/year
    before
    eGFR decline rate
    0.3 mL/min/1.73 m²/year
    on liraglutide

    Source sentences

    Summary
    The administration of liraglutide also substantially diminished the rate of decline in eGFR from 6.6 ± 1.5 mL/min/1.73 m²/year to 0.3 ± 1.9 mL/min/1.73 m²/year (p = 0.003).
    1 context sentence
    Summary · context
    Twenty-three type 2 diabetic patients with overt DN, who had already been treated with blockade of renin-angiotensin system under dietary sodium restriction, were given liraglutide for a period of 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02690883

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

Nanfang Hospital, Southern Medical Universityn = 928 Apr 2016 to 30 Dec 2019

Diabetic Nephropathies

Trial pageClinicalTrials.govUpdated 9 Mar 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.